Cargando…

Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy

Tenascin-C (TNC) is an extracellular matrix glycoprotein expressed in response to inflammation and tissue damage. The role of TNC in patients with inflammatory bowel disease (IBD) is not well understood. In this study, we analyzed the expression of TNC in the inflamed mucosa of patients with ulcerat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Longui, Li, Sha, Gao, Jianguo, Ding, Liang, Wang, Chenhui, Chen, Wenguo, Shan, Guodong, Zhang, Fenming, Yu, Jinghua, Xu, Guoqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893280/ https://www.ncbi.nlm.nih.gov/pubmed/31886172 http://dx.doi.org/10.1155/2019/1475705

Ejemplares similares

Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease
por: Ning, Longgui, et al.
Publicado: (2019)

Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease
por: Ning, LongGui, et al.
Publicado: (2019)

Effect of hepatic NPC1L1 on cholesterol gallstone disease and its mechanism
por: Mo, Pingfan, et al.
Publicado: (2023)

FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice
por: Mo, Pingfan, et al.
Publicado: (2022)

Serum proteome profiles to differentiate Crohn disease from intestinal tuberculosis and primary intestinal lymphoma: A pilot study
por: Ning, Longgui, et al.
Publicado: (2019)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn's Disease and Intestinal Tuberculosis
por: Zhang, Fenming, et al.
Publicado: (2016)

Correction: Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn’s Disease and Intestinal Tuberculosis
por: Zhang, Fenming, et al.
Publicado: (2019)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors
por: Du, Haojie, et al.
Publicado: (2020)

Imaging the Alternatively Spliced D Domain of Tenascin C in a Preclinical Model of Inflammatory Bowel Disease
por: Zhang, Liang, et al.
Publicado: (2022)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Immunomodulatory Role of Tenascin-C in Myocarditis and Inflammatory Cardiomyopathy
por: Tajiri, Kazuko, et al.
Publicado: (2021)

The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C
Publicado: (1994)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Invasion of Melanoma in Double Knockout Mice Lacking Tenascin‐X and Tenascin‐C
por: Matsumoto, Ken‐ichi, et al.
Publicado: (2002)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Advances in tenascin-C biology
por: Midwood, Kim S., et al.
Publicado: (2011)

Tenascin-C and integrins in cancer
por: Yoshida, Toshimichi, et al.
Publicado: (2015)

Immunosuppression via Tenascin-C
por: Bellone, Matteo, et al.
Publicado: (2015)

Tenascin C in Lung Diseases
por: Donovan, Chantal, et al.
Publicado: (2023)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Tenascin-C induces inflammatory mediators and matrix degradation in osteoarthritic cartilage
por: Patel, Lisha, et al.
Publicado: (2011)

High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease
por: Rodin, Isaac, et al.
Publicado: (2019)

Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update
por: Guo, Yuan, et al.
Publicado: (2013)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease
por: Hellmann, Jennifer, et al.
Publicado: (2021)

Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
por: Kolho, Kaija-Leena
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d2fkfkgmmq48o9qmlffov1ssur